Drilldown: Medicines
Medicines > routes:
IV 
& duration :
24 hours or
4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours
& duration :
24 hours or
4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours Use the filters below to narrow your results.
generic:
brand:
classes:
[[:Category:Anesthetics|Anesthetic (historical)]] (1) ·
[[:Category:Antibacterials|Antibacterial]] (2) ·
[[:Category:Antifungals|Antifungal (triazole)]] (1) ·
[[:Category:Antigout_agents|Antigout agent]] (1) ·
[[:Category:Antihyperuricemic_agents|Antihyperuricemic agent]] (1) ·
[[:Category:Arylcyclohexylamines|Arylcyclohexylamine]] (1) ·
[[:Category:Dissociatives|Dissociative]] (1) ·
[[:Category:Fluoroquinolones|Fluoroquinolone antibiotic]] (2) ·
[[:Category:NMDA_receptor_antagonists|NMDA receptor antagonist]] (1) ·
[[:Category:Sigma-1_receptor_agonists|Sigma-1 receptor agonist]] (1) ·
[[:Category:Triazoles|Triazole]] (1) ·
[[:Category:Xanthine_oxidase_inhibitors|Xanthine oxidase inhibitor]] (1)
mechanism:
uses:
'"`UNIQ--vote-00000063-QINU`"', '"`UNIQ--vote-00000064-QINU`"' (1) ·
'"`UNIQ--vote-0000030B-QINU`"', '"`UNIQ--vote-0000030C-QINU`"', '"`UNIQ--vote-0000030D-QINU`"', '"`UNIQ--vote-0000030E-QINU`"' (1) ·
'"`UNIQ--vote-00000A42-QINU`"', '"`UNIQ--vote-00000A43-QINU`"', '"`UNIQ--vote-00000A44-QINU`"', '"`UNIQ--vote-00000A45-QINU`"', '"`UNIQ--vote-00000A46-QINU`"' (1) ·
'"`UNIQ--vote-00000CEF-QINU`"', '"`UNIQ--vote-00000CF0-QINU`"', '"`UNIQ--vote-00000CF1-QINU`"', '"`UNIQ--vote-00000CF2-QINU`"', '"`UNIQ--vote-00000CF3-QINU`"', '"`UNIQ--vote-00000CF4-QINU`"' (1) ·
'"`UNIQ--vote-00000D7C-QINU`"', '"`UNIQ--vote-00000D7D-QINU`"', '"`UNIQ--vote-00000D7E-QINU`"', '"`UNIQ--vote-00000D7F-QINU`"', '"`UNIQ--vote-00000D80-QINU`"', '"`UNIQ--vote-00000D81-QINU`"' (1)
starting dose:
100 mg PO once daily; titrate by 100 mg every 2-4 weeks to a serum urate target (typically <6 mg/dL, or <5 in tophaceous disease) (1) ·
400 mg PO/IV once daily (1) ·
500-750 mg PO/IV once daily (1) ·
No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl). (1) ·
Vulvovaginal: 150 mg PO single dose; oropharyngeal: 200 mg PO day 1, then 100 mg daily ×14 days; invasive candidiasis: 800 mg load, then 400 mg PO/IV daily; cryptococcal meningitis: 400-800 mg/d (1)
preparations:
100 mg, 300 mg tablets; IV 500 mg vial (1) ·
250, 500, 750 mg tablets; 25 mg/mL oral solution; 25 mg/mL IV (premix bags 250, 500, 750 mg); 0.5%, 1.5% ophthalmic solutions (1) ·
400 mg tablets; 400 mg/250 mL IV; 0.5% ophthalmic solution (1) ·
50, 100, 150, 200 mg tablets; 10, 40 mg/mL oral suspension; 2 mg/mL IV (1) ·
Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets. (1)
fda max:
routes: (Click arrow to add another value)
onset:
duration: (Click arrow to add another value)
halflife:
1-2 hours (parent); 18-30 hours for active metabolite oxypurinol'"`UNIQ--ref-0000030F-QINU`"' (1) ·
Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1) ·
~12 hours'"`UNIQ--ref-00000D82-QINU`"' (1) ·
~30 hours (long, supports once-daily dosing and substantial drug-interaction window after discontinuation)'"`UNIQ--ref-00000A47-QINU`"' (1) ·
~6-8 hours'"`UNIQ--ref-00000CF5-QINU`"' (1)
bioavailability:
>90% (oral; not affected by food or gastric pH — a major practical advantage over itraconazole)'"`UNIQ--ref-00000A48-QINU`"' (1) ·
~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' (1) ·
~80% (oral)'"`UNIQ--ref-00000310-QINU`"' (1) ·
~90% (oral; not affected by food but reduced by divalent cations)'"`UNIQ--ref-00000D83-QINU`"' (1) ·
~99% (oral; matched 1:1 IV-to-PO conversion)'"`UNIQ--ref-00000CF6-QINU`"' (1)
pregnancy:
None (2) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Avoid in pregnancy where alternatives exist''' (animal cartilage toxicity; class-wide concern).<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited safety data; weigh benefit individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
[[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US (2) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin/levofloxacin'"`UNIQ--ref-00000D84-QINU`"' (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the same fluoroquinolone-class '''Boxed Warnings''' as ciprofloxacin: tendinitis/tendon rupture (especially elderly, corticosteroid co-use), peripheral neuropathy, CNS effects, worsening of myasthenia gravis'"`UNIQ--ref-00000CF7-QINU`"' (1)
Showing below up to 5 results in range #1 to #5.